It’s no secret that the adoption of new technologies in support of clinical trials moves at a pace considerably slower than other industries. Disruptive technologies in other sectors can change business models almost overnight. Recent examples include Uber’s transformation of the way people “hail a cab” or the uptake of consumer wearables such as FitBit and smartwatches that not only track daily activity, but also exploit social media to motivate people to exercise. Also, smartphones and tablets have changed the way that many of us do business, make purchases and interact with friends and family. These and similar innovations were in use globally within months, or even days, of their general release. The same cannot be said for innovations in the biopharmaceutical R&D environment.